No Data
Hong Kong stocks in motion | CSPC PHARMA rises over 3% as SYH2068 injection (double-stranded small interfering RNA drug) receives clinical trial approval.
CSPC PHARMA (01093) rose over 3%, as of publication, up 3.48%, priced at 6.25 Hong Kong dollars, with a transaction volume of 0.177 billion Hong Kong dollars.
CSPC PHARMA: 2024 ANNUAL REPORT
Citi is bullish on the China Medical Health Sector, with AI empowerment driving Ping An Healthcare (01833) to become the preferred stock.
Citi is bullish on the Chinese Medical and health sector, with Ping An Health and others as preferred stocks.
Disclosure of shareholder equity of Zhikong Hong Kong stocks | April 28
Disclosure of Shareholder equity in Hong Kong stocks | April 28.
Hong Kong Stock Announcement Gold Mining | BYD Company (01211) reported a net income of 9.155 billion yuan in the first quarter, an increase of 100.38% year-on-year.
SIHUAN PHARM (00460): The facial filler (child's face needle) independently developed by Meiyan Space has obtained market approval from the National Medical Products Administration; GRANDPHARMA (00512): The early detection product for urological tumors has achieved its first commercial prescription in mainland China.
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}